ChemicalBook >> CAS DataBase List >>AS2717638

AS2717638

CAS No.
2148339-28-8
Chemical Name:
AS2717638
Synonyms
AS2717638;AS2717638,AS-2717638;AS2717638, 10 mM in DMSO;6,7-Dimethoxy-2-(5-methylbenzo[d]isoxazol-3-yl)-4-(piperidine-1-carbonyl)isoquinolin-1(2H)-one;1(2H)-Isoquinolinone, 6,7-dimethoxy-2-(5-methyl-1,2-benzisoxazol-3-yl)-4-(1-piperidinylcarbonyl)-
CBNumber:
CB24844480
Molecular Formula:
C25H25N3O5
Molecular Weight:
447.48
MDL Number:
MFCD31813748
MOL File:
2148339-28-8.mol
Last updated:2025-04-18 09:51:54

AS2717638 Properties

Boiling point 712.5±60.0 °C(Predicted)
Density 1.321±0.06 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMF: 2 mg/ml; DMSO: 2 mg/ml
form A solid
pka -1.17±0.20(Predicted)
color White to off-white
UNSPSC Code 12352200

AS2717638 price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
ChemScene CS-0084785 AS2717638 98.07% 2148339-28-8 5mg $450 2021-12-16 Buy
ChemScene CS-0084785 AS2717638 98.07% 2148339-28-8 10mg $750 2021-12-16 Buy
Product number Packaging Price Buy
CS-0084785 5mg $450 Buy
CS-0084785 10mg $750 Buy

AS2717638 Chemical Properties,Uses,Production

Uses

AS2717638 is a highly selective, brain-penetrant and orally active lysophosphatidic acid receptor 5 (LPA5) antagonist with an IC50 value of 38 nM. AS2717638 is highly selective and shows no significant antagonistic activity against other LPA receptors (LPA1, LPA2, and LPA3). AS2717638 can be used in the research of pain and neuroinflammation-related diseases[1][2].

Biological Activity

Orally active, potent and selective lysophosphatidic acid (LPA) receptor LPAR5 (LPA5) antagonist with analgesic efficacy in vivo.

AS2717638 is an orally active, potent and selective lysophosphatidic acid (LPA) receptor LPAR5 (LPA5) antagonist (h/m/r LPA5 Ki = 9.1/7.3/16 nM) th at blocks LPA-induced activation of human LPA5-expressing cells (cAMP accumulation IC50 = 38 nM), but not LPA1, LPA2 or LPA3 transfectants (Ca2+ mobilization IC50 >10 μM) and displays much reduced or little affinity toward 20 other receptors and channels. AS2717638 exhibits analgesic efficacy in mice (10 & 30 mg/kg p.o. against allodynia caused by 10 ng PGE2, 300 ng PGF2α, or 3 ng AMPA per mouse via i.t.) and rats (10 mg/kg p.o. against mechanical allodynia, thermal hyperalgesia and adjuvant-induced inflammatory pain) in vivo.

in vivo

AS2717638 (3-30 mg/kg; oral administration; 1 h before the experiment; single dose) inhibits allodynia in mouse models of allodynia induced by LPA or GGPP[1].
AS2717638 (10-30 mg/kg; oral administration; 1 h before the experiment; single dose) alleviates allodynia in mouse models of allodynia induced by PGE2, PGF, or AMPA[1].
AS2717638 (10 mg/kg; oral administration; 2 h before the experiment; single dose) ameliorates static mechanical allodynia and thermal hyperalgesia in a rat model of neuropathic pain induced by chronic constriction injury (CCI)[1].
AS2717638 (10 mg/kg; oral administration; 2 h before the experiment; single dose) improves hind paw weight - bearing ability in a rat model of inflammatory pain induced by adjuvant[1].
AS2717638 (10 mg/kg; oral administration; before the experiment; single dose) reduces LPS (HY-D1056)-induced iNOS, TNFα, IL-6, and CXCL2 mRNA expression, improves the expression of neuroinflammation - related proteins, and reduces peripheral cytokine concentrations in a mouse endotoxemia model[2].

Animal Model:Male ICR mice, LPA- and GGPP-induced allodynia model[1]
Dosage:1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg (dissolved in 30% propylene glycol solvent in distilled water)
Administration:Orally, administered once, 1 h before i.t. injection of LPA or GGPP
Result:Significantly inhibited LPA- and GGPP-induced allodynia.
Animal Model:Male ICR mice, PGE2-, PGF- or AMPA-induced allodynia model[1]
Dosage:3 mg/kg, 10 mg/kg, 30 mg/kg (dissolved in 30% propylene glycol solvent in distilled water)
Administration:Orally, administered once, 1 h before i.t. injection of PGE2, PGF, or AMPA
Result:Significantly alleviated allodynia in all three pain sensitizer-induced pain models.
Animal Model:Male Sprague-Dawley rats, chronic constriction injury (CCI)-induced neuropathic pain model[1]
Dosage:10 mg/kg (dissolved in 30% propylene glycol solvent in distilled water)
Administration:Orally, administered once, 2 h before the von Frey and plantar tests
Result:Significantly ameliorated both static mechanical allodynia and thermal hyperalgesia in CCI rats.
Animal Model:Female Lewis rats, adjuvant-induced inflammatory pain model[1]
Dosage:10 mg/kg (dissolved in 30% propylene glycol solvent in distilled water)
Administration:10 mg/kg (dissolved in 30% propylene glycol solvent in distilled water)
Result:Significantly improved weight bearing difference in a rat model of adjuvant-induced inflammatory pain.
Animal Model:C57BL/6J mice (8-10 weeks, 20-30 g), mouse endotoxemia model[2]
Dosage:10 mg/kg
Administration:Orally, administered once, 24 h before sacrifice
Result:Significantly reduced the mRNA expression of iNOS, TNFα, IL6, and CXCL2.
Also amended the expression of neuroinflammatory parameters such as TLR4, Iba1, GFAP, COX-2, and the Bax/Bcl2 ratio.

IC 50

LPA5 Receptor: 38 nM (IC50, Human); LPA5 Receptor: 9.1 nM (Ki, Human); LPA5 Receptor: 16 nM (Ki, Rat); LPA5 Receptor: 7.3 nM (Ki, Mouse)

storage

Store at -20°C

References

[1] Murai N, et al. Analgesic effects of novel lysophosphatidic acid receptor 5 antagonist AS2717638 in rodents. Neuropharmacology. 2017 Nov;126:97-107. DOI:10.1016/j.neuropharm.2017.08.032
[2] Joshi L, et al. Inhibition of Autotaxin and Lysophosphatidic Acid Receptor 5 Attenuates Neuroinflammation in LPS-Activated BV-2 Microglia and a Mouse Endotoxemia Model. Int J Mol Sci. 2021 Aug 7;22(16):8519. DOI:10.3390/ijms22168519

AS2717638 Preparation Products And Raw materials

Raw materials

Preparation Products

AS2717638 Suppliers

Global( 25)Suppliers
Supplier Tel Email Country ProdList Advantage
TargetMol Chemicals Inc.
+17819995354 marketing@targetmol.com United States 32334 58
Aladdin Scientific
tp@aladdinsci.com United States 52924 58
BOC Sciences 1-631-485-4226; 16314854226 info@bocsci.com United States 12952 65
Shanghai EFE Biological Technology Co., Ltd. 021-65675885 18964387627 info@efebio.com China 9803 58
Shanghai YuanYe Biotechnology Co., Ltd. 021-61312847; 18021002903 3008007409@qq.com China 71826 60
Shanghai Chaolan Chemical Technology Center 021-QQ:65489617 15618227136 Sales@ATKchemical.com China 9342 58
Shanghai SPAR pharmaceutical technology co., LTD 021-000000 13917643586; admin@jingshipharmatech.com China 9912 58
Fan De(Beijing) Biotechnology Co., Ltd. 15911056312 liming@bio-fount.com China 9729 58
ChemeGen(Shanghai) Biotechnology Co.,Ltd. 18818260767 sales@chemegen.com China 11218 58
TargetMol Chemicals Inc. 4008200310 marketing@tsbiochem.com China 24976 58

AS2717638 Spectrum

AS2717638 1(2H)-Isoquinolinone, 6,7-dimethoxy-2-(5-methyl-1,2-benzisoxazol-3-yl)-4-(1-piperidinylcarbonyl)- AS2717638,AS-2717638 AS2717638, 10 mM in DMSO 6,7-Dimethoxy-2-(5-methylbenzo[d]isoxazol-3-yl)-4-(piperidine-1-carbonyl)isoquinolin-1(2H)-one 2148339-28-8